These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 16236629)

  • 1. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
    Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
    Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence makes perfect: the benefits of IL-2 in adoptive immunotherapy.
    Rizzuto GA; Wolchok JD
    Cytotherapy; 2005; 7(5):391-2. PubMed ID: 16236627
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation.
    Zeng M; Guinet E; Nouri-Shirazi M
    Transpl Immunol; 2009 Dec; 22(1-2):82-92. PubMed ID: 19635560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
    Chi PD; Li L; Fan YY; Wu CY
    Ai Zheng; 2007 Aug; 26(8):801-8. PubMed ID: 17697537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies.
    Li Q; Yu B; Grover AC; Zeng X; Chang AE
    J Immunother; 2002; 25(4):304-13. PubMed ID: 12142553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
    Pouw N; Treffers-Westerlaken E; Mondino A; Lamers C; Debets R
    Mol Immunol; 2010 Apr; 47(7-8):1411-20. PubMed ID: 20303179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies.
    Harada M; Okamoto T; Omoto K; Tamada K; Takenoyama M; Hirashima C; Ito O; Kimura G; Nomoto K
    Immunology; 1996 Mar; 87(3):447-53. PubMed ID: 8778032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
    Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
    Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
    Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
    Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo.
    Crossland KD; Lee VK; Chen W; Riddell SR; Greenberg PD; Cheever MA
    J Immunol; 1991 Jun; 146(12):4414-20. PubMed ID: 1674958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation.
    Sepulveda H; Cerwenka A; Morgan T; Dutton RW
    J Immunol; 1999 Aug; 163(3):1133-42. PubMed ID: 10415007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficient CD4+ T cell proliferation in the class 1 MHC-restricted 2C TCR-transgenic mouse.
    Chen FL; Kung JT
    J Immunol; 1996 Mar; 156(6):2036-44. PubMed ID: 8690890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.
    Ito F; Carr A; Svensson H; Yu J; Chang AE; Li Q
    J Immunother; 2003; 26(3):222-33. PubMed ID: 12806276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.
    Li Q; Furman SA; Bradford CR; Chang AE
    Clin Cancer Res; 1999 Feb; 5(2):461-9. PubMed ID: 10037198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.